Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors

Key Points

• The research aims to assess the incidence of hearing loss among platinum-naïve patients treated with immune checkpoint inhibitors.
• Monitored patients receiving immune checkpoint inhibitors
• Employed standardized audiologic surveillance
• Analyzed criteria for hearing loss
• A significant proportion of patients experienced hearing loss
• Need for further studies to quantify ICI ototoxicity
• Current findings highlight potential risks associated with treatment